Ayelet Chajut
Plus aucun poste en cours
Profil
Ayelet Chajut worked as Vice President-Research at Pluri, Inc., Vice President-Research at Quark Pharmaceuticals, Inc., and Executive Vice President-Research & Development at Rosetta Genomics Ltd.
She holds a doctorate degree from Tel-Aviv University.
Anciens postes connus de Ayelet Chajut
| Sociétés | Poste | Fin |
|---|---|---|
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Directeur Technique/Scientifique/R&D | - |
| PLURI INC. | Directeur Technique/Scientifique/R&D | - |
| ROSETTA GENOMICS LTD. | Directeur Technique/Scientifique/R&D | - |
Formation de Ayelet Chajut
| Tel-Aviv University | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ROSETTA GENOMICS LTD. | Health Technology |
| PLURI INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |